Assisted Reproduction Safety and Risks

Congenital malformations of newborn infants after clomiphene-induced ovulation

Kurachi K, Aono T, Minagawa J, Miyake A

Published August 1983 Fertility and Sterility, 40(2), 187-189
DOI 10.1016/s0015-0282(16)47235-3 PMID 6873315

RRM Academy Synopsis

Birth defect rates after clomiphene matched spontaneous ovulation

A prospective study in Japan found that birth defect rates after clomiphene treatment did not differ significantly from rates after spontaneous ovulation. Nine university hospitals contributed 1034 women who conceived on clomiphene. The comparison group was 29,900 women who ovulated on their own.

Key Findings

  • Of 935 infants born after clomiphene, 21 had visible malformations: 9 infants had major malformations and 12 had minor ones.
  • Among 30,033 infants after spontaneous ovulation, 520 (1.7%) had malformations: 332 (1.1%) major and 188 (0.6%) minor.
  • Malformations after clomiphene did not differ significantly from the 1.7% after spontaneous ovulation or the 1.9% (4 of 213 infants) in the hMG-hCG group.
  • Pregnancy loss before the 24th week totaled 14.8% after clomiphene, against 13.9% after spontaneous ovulation. Abortion accounted for 147 of 1034 pregnancies (14.2%).
  • Stillbirth occurred in 14 of 881 clomiphene pregnancies (1.6%). The malformation rate showed no relationship to the clomiphene dose or to the mother's age.

Interpretation

The investigators followed all recorded pregnancies prospectively and examined newborns for visible malformations within 1 week after birth. Two comparison groups were used: women after spontaneous ovulation and women after hMG-hCG treatment. Mean maternal age was similar in the clomiphene and spontaneous ovulation groups (28.58 and 28.48 years). Logistic regression analysis tested the differences. The types of malformations matched those in the spontaneous ovulation group, and none was specific to clomiphene. The authors concluded that clomiphene at a suitable dose has no teratogenic effect.

RRM Context

Restorative reproductive medicine begins with the cause of ovulation problems and evaluates both partners. A drug that induces ovulation acts on the missing event itself. This 1983 Japanese series adds a record of birth defect rates to the evidence clinicians weigh beside a cause-based workup.

Abstract

The effect of clomiphene citrate (CC) on the incidence of congenital malformations in newborn infants was assessed from the outcome of 1034 pregnancies after CC-induced ovulation recorded at nine university hospitals in a 5-year period. Of these pregnancies, 14.2% ended in abortion, 0.5% in ectopic pregnancy, 0.1% in molar pregnancy, and 1.6% in stillbirth. In all, 935 infants were born, and 21 (2.3%) showed visible malformations. This incidence of malformations was not significantly different from that in 30,033 infants (1.7%) after spontaneous ovulation (spontaneous ovulation group), and the types of malformations after CC treatment were similar to e those in the spontaneous ovulation group. These data indicate that CC has no teratogenic effect.

Topics

By this author

Related research

Assisted Reproduction › Safety and Risks › Birth Defects · Pregnancy › Neonatal Outcomes › Neonatal Morbidity · Therapeutics › Ovulation Agents › Selective Estrogen Receptor Modulators
Keiichi Kurachi, Toshihiro Aono, Junnosuke Minagawa, Akira Miyake
K Kurachi, T Aono, J Minagawa, A Miyake
PMID 6873315 6873315 DOI 10.1016/s0015-0282(16)47235-3 10.1016/s0015-0282(16)47235-3 Kurachi et al. 1983, Kurachi 1983